Published in PLoS One on July 06, 2015
A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst (2000) 3.98
Ovarian cancer. Lancet (2009) 3.95
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res (1999) 2.00
Structure, function and regulation of the ABC1 gene product. Curr Opin Lipidol (2001) 1.64
ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecol Oncol (2013) 1.61
Mechanisms of drug resistance in cancer chemotherapy. Med Princ Pract (2005) 1.57
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res (2004) 1.54
Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cancer Lett (2010) 1.51
Second-line treatment of ovarian cancer. Oncologist (2000) 1.45
Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol (2004) 1.33
Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene (2010) 1.26
Prevalent loss of mitotic spindle checkpoint in adult T-cell leukemia confers resistance to microtubule inhibitors. J Biol Chem (2001) 1.23
The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. Pharmacol Rev (2006) 1.16
Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol (2003) 1.12
Expression of M2-polarized macrophages is associated with poor prognosis for advanced epithelial ovarian cancer. Technol Cancer Res Treat (2012) 1.11
Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Cytokine (2011) 1.11
SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. Cancer Res (2005) 1.07
Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer (2012) 1.01
Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol (2002) 1.00
Induction of MDR1-gene expression by antineoplastic agents in ovarian cancer cell lines. Anticancer Res (2002) 0.97
Regulation of ovarian cancer stem cells or tumor-initiating cells. Int J Mol Sci (2013) 0.95
Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther (2011) 0.91
MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumors. Cancer Lett (1996) 0.88
Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells. Int J Gynecol Cancer (2005) 0.84
Interval debulking surgery for advanced epithelial ovarian cancer. Cochrane Database Syst Rev (2013) 0.84
Clinical significance of ascites in epithelial ovarian cancer. Neoplasma (2013) 0.81
[Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines]. Zhonghua Zhong Liu Za Zhi (2001) 0.77